Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Myeloid 1

Conditions

Leukemia, Myeloid, Acute 59Myelodysplastic Syndromes 14Leukemia 11Recurrence 5Leukemia, Promyelocytic, Acute 5Congenital Abnormalities 5Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Erythroblastic, Acute 4Anemia, Refractory, with Excess of Blasts 4Leukemia, Megakaryoblastic, Acute 3Neoplasm, Residual 2Leukemia, Myelomonocytic, Juvenile 2Leukemia, Myelomonocytic, Chronic 2Sarcoma, Myeloid 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myeloproliferative Disorders 1Leukemia, Myelogenous, Chronic, BCR-ABL Positive 1Leukemia, Lymphocytic, Chronic, B-Cell 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Disease Progression 1Disease 1Blast Crisis 1

Interventions

Cyclophosphamide 81fludarabine phosphate 77Peripheral Blood Stem Cell Transplantation 62Mycophenolic Acid 55Tacrolimus 54Whole-Body Irradiation 52Busulfan 51Antilymphocyte Serum 45Cyclosporine 41fludarabine 36Methotrexate 32Filgrastim 32Melphalan 30Radiotherapy 25Methylprednisolone 19Cytarabine 17Cord Blood Stem Cell Transplantation 17Sirolimus 15Azacitidine 15Granulocyte Colony-Stimulating Factor 14Alemtuzumab 14thymoglobulin 13Flow Cytometry 13Etoposide 13Cyclosporins 13Specimen Handling 10Biopsy 10Thiotepa 9Psychiatric Rehabilitation 9Decitabine 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Myeloproliferative Disorders × Gemtuzumab × Clear all
NCT03589729 2026-05-22

Dexrazoxane Hydrochloride in Preventing Heart-Related Side Effects of Chemotherapy in Participants With Blood Cancers

M.D. Anderson Cancer Center

Phase 2 Recruiting
100 enrolled
MyeloidOther hematologic neoplasmSarcoma

Blast Crisis, Myeloproliferative Disorders, Leukemia, Myeloid, Acute, Sarcoma, Myeloid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡